there is currently an intense focus on multi-drug resistant pathogens that render last-21 line antimicrobial treatments ineffective [1][2][3] . We question the current emphasis of 22 attention on resistance to last-line antimicrobials, arguing that tackling resistance to 23 front-line antimicrobials has a greater public health benefit. Using AMR monitoring 24 data on 25 drug-pathogen combinations from across Europe 4 , here we show that the 25 presence of front-line pathogen resistance initiates a cascade of resistance selection that 26 ultimately leads to pathogen resistance to last-line antimicrobials. We then interrogate, 27 by modelling the dynamics of resistance evolution, whether 3 key interventions in the 28 strategic response to AMR are more effectively targeted at front-line or last-line 29 treatment. We show that interventions that make front-line therapy more effective by 30 use of antimicrobial adjuvants or front-line resistance diagnostics or by introduction of 31 a novel, front-line antimicrobial all lead to a larger reduction in mortality and 32 morbidity than the same interventions implemented in last-line therapy. Mass use of a 33 newly discovered antimicrobial in front-line infection management to maximise its 34 public health benefit is contrary to current policy 5 but may provide valuable incentives 35 for drug developers. We demonstrate that funding, publications, and attention to those 36 publications do not reflect the importance of front-line antimicrobials and are 37 disproportionately devoted to last-line antimicrobials that account for less than 10% of 38 antimicrobial prescriptions 6,7,8 . While studying resistance to last-line drugs is 39 undoubtedly important, our work relays a strong message to public health agencies, 40 funding bodies, and researchers that allocating resources to front-line infections can be 41 a more effective way to combat the antimicrobial resistance crisis. 42 43 Antimicrobial resistance (AMR) is predicted over time to significantly increase rates of 44 morbidity, mortality, and healthcare expenditure, as well as adversely affect medical 45 advances in all clinical specialties 9 . The medical and scientific communities have reacted 46 with a broad multi-disciplinary approach including antimicrobial stewardship programmes 10 , 47 AMR diagnostic development 11,12 , microbiology of resistance 13,14 and development of 48 antimicrobial adjuvants and alternatives to antimicrobials 15 . Multi-faceted attempts are being 49 made to incentivise and promote new antimicrobial drug development 16,17 . However, the vast 50 scale of investment required to combat the antimicrobial resistance crisis was recently 51 estimated to be somewhere between the Large Hadron Collider project (£6 billion) and the 52 International Space Station ($96 billion) 18 . 53
would then expect the declining efficacy of front-line drugs to force the use of another, less 76 commonly used antimicrobial agent, typically with a different mechanism of action. This 77 exposure in turn increases the risk of resistance development to the second antimicrobial, and 78 so the cascade of antimicrobial use and resistance continues, ultimately leading to pathogens 79 resistant to last-line antimicrobials. 80 81 While this cascade of selection pressures is often implicitly assumed in the literature 82 (sometimes conceptualised as a drug "Treadmill" 22 ) there have been no tests of its 83 occurrence. We assessed whether there is epidemiological evidence for a cascade of selection 84 for resistance using European Centre for Disease Control antimicrobial resistance data from 85 2000 to 2015 for 7 pathogens (Escherichia coli, Pseudomonas aeruginosa, Klebsiella 86 pneumoniae, Acinetobacter spp., Enterococcus faecalis, Enterococcus faecium, and 87
Streptococcus pneumoniae) 4 and the antimicrobials routinely used to treat them. Using 88 mixed effects modelling, we asked how changes in levels of resistance to drug A will have 89 future effects on levels of resistance to drugs B, C, D, etc. For example, for E. coli, an 90 increase in frequency of resistance to the recommended front-line aminopenicillins will 91 necessitate the increased use of aminoglycosides, fluoroquinolones or cephalosporins, which 92 is reflected by an increase in the frequency of resistance to these antimicrobials in the 93 subsequent year ( Fig. 1a, Supplementary Data) . For K. pneumoniae, which has a narrower 94 palette of clinically effective antimicrobials, the appearance of resistance to the 95 recommended front-line treatment with cephalosporins directly leads to increased use of the 96 last-line drug meropenem and thus increased frequency of meropenem resistant strains in the 97 subsequent year ( Fig. 1c, Supplementary Data) . Overall, our model demonstrates that 98 increases in frequency of resistance to any antimicrobial leads to increases in frequency of 99 strains resistant to other antimicrobials in subsequent years in 57 out of 72 (79%) inter-drug relationships ( Fig. 1, Supplementary Data) . Resistance in fluoroquinolones and 101 cephalosporins in K. pneumoniae alone show the opposite relationship; this warrants further 102 investigation. Overall, however, our analysis strongly supports the theory of a cascade of 103 resistance selection from front-line to last-line antimicrobials as the general pattern of MDR 104 evolution. 105 106 Given that last-line drug resistance evolves via a cascade of selection following the 107 appearance of resistance to front-line drugs where should we focus our intervention efforts to 108 maximise public health benefit? We hypothesised that focussing our efforts on front-line 109 interventions that optimise efficient clearance of pathogens resistant to front-line drugs will 110 ultimately have the largest public health benefit. The three interventions that we have 111 examined are key areas in the strategic response to AMR: 1) introduction of antimicrobial 112 adjuvants that maximise efficacy of existing antimicrobials against resistant strains, 2) 113 introduction of point-of-care resistance diagnostics, and 3) introduction of a brand-new 114 antimicrobial with a novel mechanism of action. 115
116
To test our front-line hypothesis, using a susceptible-infected compartmental model we 117 does not clear. The clearance and onward transmission of each strain within and between 126 carrier and symptomatic classes is affected by susceptibility to the treatment and the cost of 127 resistance mutations, and we allow for the de novo evolution of resistance during treatment. 128 Individuals within the 'carrier' class can be colonised with any strain. Since individuals in 129 this class do not develop disease due to our focal pathogen, they do not receive treatment for 130 our focal pathogen. However, carriers can receive antimicrobial treament for an infection 131 with a different pathogen, or owing to inappropriate antimicrobial usage (e.g. self-medication 132 or use of an antibiotic to treat a viral infection). This exposure to antimicrobials while in the 133 pathogen is in carriage and not the target of treatment is referred to as "bystander 134 selection" 19 . We let the level of resistance evolve in this population for a specified burn-in 135 time period and then evaluated the benefit of the intervention for a period of time after the 136 intervention. We used four different measures of public health outcomes. At the population 137 level, we assessed the total disease induced mortality after intervention, and the average 138 prevalence of infection (as a measure of disease induced morbidity). At the individual patient 139 level we assessed the probability that a patient dies of their infection once infected, and also 140 the average duration of infection as a measure of morbidity. 141
142
We first examine the effects of a hypothetical antimicrobial adjuvant that partially restores 143 the efficacy of a drug against resistant pathogens. This could, for example, represent 144 optimisation of drug delivery to increase an effective dose against a resistant strain 23 or 145 addition of molecules targeting resistance mechanisms, e.g. novel beta-lactamase inhibitors 146 or novel CRISPR phage therapeutics 15, 18, 24 . We find that focussing on optimising front-line 147 treatment (i.e. with adjuvants to increase the clearance of front-line resistant strains) 148 decreases the basic reproductive number (R 0 ) of MDR strains to a greater extent than last-line 149 intervention ( Supplementary Fig. 1 ), and leads to better public health outcomes ( Fig. 2 , Supplementary Fig. 2 ). This is particularly evident in the demarcated area that represents 151 current antimicrobial usage patterns, where front-line drugs account for 90% to 97% of 152 antimicrobial prescriptions and the percentage of antimicrobial exposures that constitute 153 bystander selection ranges from 44% to 94% (Fig. 2, previous clinical studies which demonstrate the positive impact of prompt appropriate 173 antimicrobial therapy on morbidity and mortality 26 . We note however, that in the absence of 174 other interventions both front-line and last-line diagnostics have no effect on the fitness of MDR strains -there is no advantage to knowing that these strains are resistant when there is 176 no alternative drug to which they are sensitive ( Supplementary Fig. 1 ) 27 . 177 178 Finally, to assess where in the treatment hierarchy to deploy a newly developed antimicrobial 179 we extend our model to three different antimicrobials. We consider two scenarios: 1) 180 reservation of the new antimicrobial as a last-line drug (as is current policy 5 ) and 2) 181 deployment of the new antimicrobial as a new front-line drug. The model shows clearly here 182 that deployment of a newly discovered drug as a front-line treatment leads to greater 183 reductions in mortality and morbidity than saving this drug for last-line therapy ( Figure 2 arguing currently that there is no financial incentive for them to discover a new antimicrobial 206 that will only be used sparingly because it is being preserved carefully for patients who have 207 MDR pathogens 5 . Our work clearly shows that there is a strong public health advantage to a 208 new drug being introduced in front-line settings, as it ultimately will lead to the largest 209 reductions in morbidity and mortality. Promised bulk use of a new agent is far more 210 economically attractive to drug companies and would help to promote novel antimicrobial 211 research and development to provide the healthy drug pipeline required. 212
213
Our models clearly demonstrate the benefit of front-line interventions but we show below 214 that the research community is focussing disproportionately on last-line resistance. Hitherto, 215 there has been no published data on how much research effort in response to the AMR crisis 216 is allocated to front-line or last-line antimicrobials. We addressed this information gap by 217 combining data for 13 antimicrobial classes on worldwide antimicrobial usage 6 with six 218 different measures of research focus. We assessed the level of funding research into 219 resistance to each antibiotic class using both total grant dollars awarded and total numbers of 220 active grants from the National Institute for Health (NIH), the world's largest public 221 biomedical funder 28 . We quantified the current focus of research groups using numbers of 222 research papers published since 2012 focusing on resistance to each antibiotic class. Finally, 223
we used three different measures of the attention these papers received using Altmetric, a 224 service that tracks the online sharing and coverage of research 29 . In all cases, we find that there is no correlation between research focus on different antibiotic classes and their usage, 226 with infrequently used last-line drugs receiving a disproportionate amount more funding, 227 published research articles, and attention to those articles compared to expectation based on 228 their usage ( Fig. 3, Supplementary Fig. 7 , Supplementary Table 1 ). The extent of this 229 disproportionate focus is extreme. Penicillins constitute 38% of global antimicrobial usage, 230 while carbapenems constitute just 0.2% of usage, yet research into carbapenem resistance 231 received more funding than penicillin resistance. The seven least commonly used classes of 232 antimicrobials (Chloramphenicols, Aminoglycosides, Carbapenems, Rifamycin, 233
Glycopeptides, Monobactams, and Polymixins) constitute only 3% of global usage yet 234 received 47% of research funding. This pattern is also not explained by newer antimicrobial 235 classes, where it is likely that less is known about resistance mechanisms, receiving more 236 attention as we found no relationship between the age of an antimicrobial class and any 237 attention metrics ( Supplementary Figure 8 , Supplementary Table 2) . 238 239 Our analysis of current research practices demonstrates that current research focuses 240 disproportionately on resistance to last-line antimicrobials: we are focusing on the end of the 241 resistance cascade, rather than the beginning. The fundamentals of medicine and 242 epidemiology teach us that such an approach may be misguided -it is generally better to 243 tackle a disease process in its early stages to prevent future clinical events, which carry 244 substantial morbidity. Our epidemiological analysis and mathematical modelling show that 245 the old adage 'look after the pennies and the pounds will look after themselves' can be 246 applied; if the treatment of front-line resistant pathogens is optimised this has a greater public 247 health impact than focussing on last-line resistant pathogens. 248
The occurrence of MDR pathogens that are resistant to last-line antimicrobials such as 250 carbapenems is a public health emergency and requires attention. However, as a medical 251 and research community we need to act in a way that will minimise the ongoing impact of 252 AMR and use our resources and any newly discovered antimicrobials to achieve the most 253 substantial decreases in morbidity and mortality. Our results show that the way to utilise 254 resources most effectively is to urgently re-evaluate our priorities and increase our focus on 255 ways to tackle resistance to front-line antimicrobials. 
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Methods: 569
Analysis of ECDC data on frequency of resistance. To assess whether resistance to other 570 drugs results in increases in resistance to a focal drug we used data from the ECDC's 571 European Antimicrobial Resistance Surveillance Network (EARS-Net). This database 572 includes data on the percentage isolates resistance to a range of antibiotics for 7 pathogen 573 species (Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter 574 spp., Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, and 575
Staphylococcus aureus) for 30 European countries from 2000 to 2015 (though some 576 pathogens are only available more recently) and is available at http://atlas.ecdc.europa.eu. We 577 omitted Staphylococcus aureus from our analysis as only data on methicillin resistance are 578 available, so it cannot be used to assess effects of levels of resistance of different drugs on a 579 focal drug's resistance dynamics. All resistance data (percentage of isolates resistant) were 580 log-odds transformed prior to analysis to homogenise variance. For each antibiotic and 581 pathogen for which data were available we fit a random effects model of the following form 582 !,!,!!! = !,! + !,! !,!,! ! + !,! + !,! + where !,!,!!! is the change in the log-odds of resistance (first difference) between year t and 583 t + 1 in country i for antibiotic k, !,! is the intercept, !,!,!!! is the level of resistance in 584 country i for antibiotic j in year t, !,! is the effect of resistance level for antibiotic j on the 585 change in resistance for the focal antibiotic, !,! is a trend in the change in resistance 586 frequency, ! is a random effect of country, and is the normally distributed error term. All 587 models were fitted in R using the lme4 package. Full model results are given in 588 Supplementary Data. 589
Mathematical model of intervention consequences. In order to assess whether 591 interventions to tackle last-line or front-line drug resistance would have the greatest public 592 health benefit we modelled the dynamics of resistance evolution using a susceptible-infected 593 compartmental model. We considered a scenario where patients initially receive a front-line 594 antibiotic and then transition to last-line antibiotic treatment at a constant rate if they remain 595 infected. All infections are cleared at a baseline rate, with additional clearance rate when 596 treated with an antibiotic to which the infecting strain is susceptible. Ill patients die from 597 infection at a constant rate. Each resistance mutation increases a strain's clearance rate, 598
representing the cost of resistance. Each strain also transmits to uninfected individuals at 599 equal rates. Patients can be infected with four different strains, a susceptible strain , a strain 600 resistant to the front-line drug , a strain resistant to the last-line drug , and a multi-drug 601 resistant strain carrying both resistance mutations . We further assume that some 602 individuals carry the infection asymptomatically ("carriers"). The pathogen may still 603 experience exposure to antimicrobial usage when in carriage either owing to its use to treat 604 other infections or because of inappropriate usage (e.g. use of an antibiotic to treat viral 605 infections). This exposure to the antimicrobial when not causing symptoms is termed 606 "bystander selection". We assume that the focal pathogen only experiences bystander 607 selection for the front-line drug as there are no current estimates of bystander selection for 608 last-line drugs and this assumption works against our hypothesis by increasing selection for 609 resistance to front-line drugs. We considered three possible interventions: introduction of an 610 adjuvant that blocks the resistance mechanism, introduction of a diagnostic to detect 611 resistance and avoid use of the antimicrobial when resistance is present, and introduction of a 612 novel antimicrobial drug. We evaluated the effects of each intervention in terms of four
